The 10-K mentions a definitive agreement to acquire Paragon 28, Inc., a company focused on the foot and ankle orthopedic segment, for approximately $1.2 billion in initial consideration. This acquisition is expected to expand Zimmer Biomet's product offerings and market presence in this area.

The 10-K discusses the 2023 Restructuring Plan, which aims to reduce costs and improve efficiency. The plan is expected to generate significant pre-tax operating expense reductions by the end of 2025.

The implementation of a new ERP system in the U.S. and Canada caused operational challenges and affected the ability to fulfill customer orders, leading to a negative impact on net sales. Shipping levels returned to normal by the end of the year.

The 10-K details several acquisitions completed in 2024, including companies focused on sports medicine, CMFT, and hip replacement technologies. These acquisitions demonstrate management's commitment to expanding the product portfolio and entering new market segments.

The 10-K indicates that the 2023 Restructuring Plan is progressing, with expenses recognized and expected cost reductions. This suggests management is actively working to improve operational efficiency and profitability.

The difficulties encountered during the ERP system implementation demonstrate potential execution risks associated with large-scale technology projects and the importance of effective project management.

The 10-K acknowledges that the company has substantial indebtedness and may incur additional debt in the future. This could reduce funds available for working capital, capital expenditures, and other corporate requirements, and limit flexibility in responding to changes in the business and industry.

The 10-K discusses the company's dependence on sophisticated information technology and the risk of security breaches, cyber attacks, and other disruptions that could compromise confidential information and disrupt operations.

The 10-K highlights the risk of failing to comply with healthcare fraud and abuse laws and regulations, which could result in substantial penalties and negatively affect the business, operations, and financial condition.

The 10-K states that the orthopedics and broader musculoskeletal care industry is highly competitive, with major competitors including Johnson & Johnson MedTech, Stryker Corporation, and Smith & Nephew plc.

The 10-K emphasizes that a key factor in the company's continuing success is its ability to develop new products and technologies and improve existing products and technologies.

The 10-K mentions that the company is subject to cost containment measures in the United States and other countries, resulting in pricing pressures.

The 10-K states that the company has improved manufacturing processes to harmonize and optimize quality systems and to protect profitability and offset the impact of inflationary costs.

The 10-K indicates that the transition to a new ERP system disrupted the ability to fulfill customer orders, highlighting potential operational bottlenecks.

The 10-K notes that the global supply chain has been and continues to be negatively impacted by a variety of macro factors, which have, in part, resulted in challenges to meet end market demand.

The 10-K highlights extensive research and development activities to develop new surgical techniques, including robotic techniques, materials, biologics and product designs.

The 10-K describes the ZBEdge Platform, which connects robotic and digital technologies to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care.

The 10-K mentions the company is broadening its offerings in certain product categories and exploring new technologies, including artificial intelligence and machine learning, with possible applications in multiple areas.

The 10-K discusses the issuance of senior notes and the intended use of the proceeds, including stock repurchases, debt redemption, and funding the Paragon 28 acquisition.

The 10-K mentions that in May 2024, the Board of Directors authorized a $2.0 billion share repurchase program.

The 10-K details several acquisitions completed in 2024 and planned for 2025, demonstrating a focus on strategic acquisitions to grow the business.

The 10-K states that the company's mission is to alleviate pain and improve the quality of life for people around the world, and that this commitment shapes all day-to-day decisions.

The 10-K discusses team member inclusion efforts to identify, attract and retain talent for the business, and monitoring and benchmarking team member demographics.

The 10-K highlights the company's focus on the physical and mental health, financial wellbeing, and work/life balance of its employees, and the sponsorship of wellness programs.

The 10-K notes that the business is seasonal in nature to some extent, as many of the products are used in elective procedures, which typically decline during the summer months and can increase at the end of the year once annual deductibles have been met on health insurance plans.

The 10-K states that international operations are subject to a number of risks and potential costs, including changes in foreign medical reimbursement policies and programs, differing local product preferences, and fluctuations in foreign currency exchange rates.

The 10-K mentions that tariffs, trade restrictions and other trade measures could prevent the company from shipping products to or from a particular market, restrict access to certain sources of raw materials and other inputs, increase operating costs and disrupt the ability to collect payment for our products and services in particular markets.